MedPath

Treatment With Aspirin After Preeclampsia: TAP Trial

Phase 4
Recruiting
Conditions
Hypertension;Pre-Eclamptic
Hypertensive Disorder of Pregnancy
Pre-Eclampsia
Gestational Hypertension
Cardiovascular Diseases
Toxemia
Pregnancy Complications
Hypertension, Pregnancy Induced
Eclampsia
Vascular Diseases
Interventions
Registration Number
NCT06281665
Lead Sponsor
Alisse Hauspurg
Brief Summary

The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.

Detailed Description

This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Postpartum individuals ≥18 years old
  • Preeclampsia diagnosis
Exclusion Criteria
  • Fetal anomaly
  • Multiple gestation
  • Pre-pregnancy hypertension
  • Allergy or contraindication to low-dose aspirin
  • Pre-pregnancy diabetes

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo GroupPlaceboSimilar appearing placebo pill daily for 6 months will be given to subjects.
Intervention GroupLow-dose aspirinLow-dose \[81 mg\] aspirin pill daily for 6 months will be given to subjects
Primary Outcome Measures
NameTimeMethod
Percent of participants eligible, enrolled and retained (feasibility)Baseline to approximately 6 months postpartum

To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia.

Secondary Outcome Measures
NameTimeMethod
Mean daytime mean arterial pressure6 months postpartum

Mean daytime mean arterial pressure on ambulatory blood pressure monitoring

Mean overall systolic blood pressure6 months postpartum

Mean overall systolic blood pressure on ambulatory blood pressure monitoring

Mean overall diastolic blood pressure6 months postpartum

Mean overall diastolic blood pressure on ambulatory blood pressure monitoring

Endothelial function Emax6 months postpartum

Emax from microiontophoresis

Endothelial function change in EC50%2 to 6 months postpartum

Change in EC50% between visits

Change in systolic blood pressure2 to 6 months postpartum

Change in study visit mean systolic blood pressure between visits

Study visit diastolic BP6 months postpartum

Mean study visit diastolic BP

Study visit systolic BP6 months postpartum

Mean study visit systolic BP

Endothelial function EC50%6 months postpartum

EC50% from microiontophoresis

Change in diastolic blood pressure2 to 6 months postpartum

Change in study visit mean diastolic blood pressure between visits

Change in mean arterial pressure2 to 6 months postpartum

Change in study visit mean arterial pressure between visits

Anti-hypertensive medication use6 months postpartum

Use of anti-hypertensive medication (percent of participants)

Therapeutic intensity score6 months postpartum

Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome)

Mean home diastolic blood pressuredelivery through 6 months postpartum

Mean home diastolic blood pressure

Mean home mean arterial pressuredelivery through 6 months postpartum

Mean home mean arterial pressure

Study visit mean arterial pressure6 months postpartum

Mean study visit mean arterial pressure ((2\*diastolic BP + systolic BP / 3))

Mean nocturnal systolic blood pressure6 months postpartum

Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring

Mean daytime diastolic blood pressure6 months postpartum

Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring

Classification of hypertension6 months postpartum

Stage 1, stage 2 hypertension (percent of participants with each stage)

Mean home systolic blood pressuredelivery through 6 months postpartum

Mean home systolic blood pressure

Mean overall mean arterial pressure6 months postpartum

Mean overall mean arterial pressure on ambulatory blood pressure monitoring

Mean daytime systolic blood pressure6 months postpartum

Mean daytime systolic blood pressure on ambulatory blood pressure monitoring

Mean nocturnal diastolic blood pressure6 months postpartum

Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring

Mean nocturnal mean arterial pressure6 months postpartum

Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring

Endothelial function change in Emax2 to 6 months postpartum

Change in Emax between visits

Trial Locations

Locations (1)

University of Pittsburgh Magee-Womens Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath